Quick Answer
Immix Biopharma, Inc. reported Stockholders Equity of $93.80 million for fiscal year 2025.
Immix Biopharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $93.80M | +607.8% |
| 2024 | $13.25M | -19.2% |
| 2023 | $16.41M | +24.7% |
| 2022 | $13.16M | -26.8% |
| 2021 | $17.99M | +480.3% |
| 2020 | -$4.73M | -29.7% |
| 2019 | -$3.65M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.26M | -52.9% | +77.6% |
| June 30, 2025 | $4.65M | -80.5% | -51.5% |
| March 31, 2025 | $9.59M | -65.6% | -27.6% |
| December 31, 2024 | $13.25M | -19.2% | -24.5% |
| September 30, 2024 | $17.55M | -11.2% | -26.5% |
| June 30, 2024 | $23.89M | +80.6% | -14.4% |
| March 31, 2024 | $27.92M | +137.2% | +70.2% |
| December 31, 2023 | $16.41M | +24.7% | -17.0% |
- Immix Biopharma, Inc. showed an increase of +607.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Immix Biopharma, Inc.’s stockholders equity has grown by 2672.3% (from -$3.65 million to $93.80 million).
- The most recent figure is from Immix Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: